



康臣藥業集團有限公司  
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)  
(於開曼群島註冊成立的有限公司)  
(Stock code / 股份代碼: 1681)

---

NOTIFICATION LETTER

---

19 September 2025

Dear Registered Shareholders,

**Consun Pharmaceutical Group Limited (“Company”)**  
**– Notice of Publication of Interim Report 2025 (the “Current Corporate Communications”)**

The Current Corporate Communications of the Company have been published in English and Chinese languages and are available on the website of The Stock Exchange of Hong Kong Limited (“HKEX”) at [www.hkexnews.hk](http://www.hkexnews.hk) and the Company’s website at [www.chinaconsun.com](http://www.chinaconsun.com). If you have any difficulty in receiving or gaining access to the Current Corporate Communications posted on the Company’s website for any reason, please send your request (specifying your name, address and request) by email at [consunpharma.ecom@computershare.com.hk](mailto:consunpharma.ecom@computershare.com.hk) or by notice in writing to the Company’s Hong Kong branch share registrar (the “Branch Share Registrar”), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong. The Company will promptly upon receipt of your request send the Current Corporate Communications to you in printed form free of charge.

**Arrangement of Electronic Dissemination of Corporate Communications**

Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) the Company is writing to inform you that the Company has adopted electronic dissemination of Corporate Communications, which mean any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the annual report and, where applicable, its summary annual report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at [www.chinaconsun.com](http://www.chinaconsun.com) and the HKEX website at [www.hkexnews.hk](http://www.hkexnews.hk) in place of printed copies.

**Solicitation of electronic contact details**

To ensure timely receipt of the latest Corporate Communications in future, the Company recommends you provide your email address by scanning your personalized QR code printed on the enclosed reply form (the “Reply Form”). Alternatively, you may sign and return the Reply Form to the Branch Share Registrar.

**If the Branch Share Registrar does not receive a functional email address from you, until such time that the functional email address is provided to the Branch Share Registrar, the Company will send to you by post (i) a notification letter of the publication of the Corporate Communications on the Company’s website; and (ii) all future Actionable Corporate Communications in printed form together with a request form for functional electronic communication details of the shareholder.**

If you want to receive the future Corporate Communications and/or Actionable Corporate Communications in printed form, please complete and return the Reply Form to the Branch Share Registrar or send an email to [consunpharma.ecom@computershare.com.hk](mailto:consunpharma.ecom@computershare.com.hk) specifying your name, address and request to receive the Corporate Communications and/or Actionable Corporate Communications in printed form. Please note that your request shall be valid for one year starting from the receipt date of your Reply Form and will expire thereafter, unless it is revoked or superseded before its expiry.

Please be reminded that provision of your correct and effective contact details (including email address and mailing address) to the Company and/or the Branch Share Registrar is critically important, and any mistakes in such details may result in failure of delivery of the Company’s Corporate Communications and/or Actionable Corporate Communications to you timely in the future.

Should you have any queries relating to this letter, please contact the Branch Share Registrar at (852)2862 8688 during business hours from 9:00 a.m. to 6:00 p.m. (Hong Kong time), Mondays to Fridays, excluding Hong Kong public holidays.

Yours faithfully,  
By order of the Board of  
Consun Pharmaceutical Group Limited  
An Meng  
Chairman

Note: Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including, but not limited to, (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) notices of meeting; (d) listing documents; (e) circulars; and (f) proxy forms. Pursuant to Rule 1.01 of the Listing Rules, Actionable Corporate Communications are any corporate communications that seek instructions from issuer’s securities holders on how they wish to exercise their rights or make an election as the issuer’s securities holder.

